Skip to Content
Home > About Us > Research and Grants Administration > Results
The purpose of this study is to compare any good and bad effects patients with early stage non-small cell lung cancer that was surgically removed may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).
The purpose of this research study is to look at lung cancer patients’ tumors that were removed by surgery for certain genetic changes, and to possibly offer these patients a treatment study with drugs that may specifically target tumors that have these genetic changes.
The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for patients with ALK-positive non-small cell lung cancer.
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO®), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer.
View Additional Section Content
For more information about our research program and IRB, please contact: